Trial Profile
A study to evaluate incidence, clinical characteristics, predicting factors and primary resistance to sunitinib in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 02 Sep 2015 New trial record